PCM
IRON icon

Prelude Capital Management’s Disc Medicine IRON Stock Holding History

Prelude Capital Management’s Portfolio IRON Stock Details IRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,985
Closed -$1.11M – 1396
2025
Q4 		$1.11M Sell
13,985
-4,171
-23% -$352K 0.08% 273
2025
Q3 		$1.2M Hold
18,156
– – 0.09% 273
2025
Q2 		$962K Sell
18,156
-44
-0.2% -$2.07K 0.09% 269
2025
Q1 		$903K Buy
18,200
+44
+0.2% +$2.45K 0.07% 336
2024
Q4 		$1.15M Buy
18,156
+4,156
+30% +$240K 0.07% 347
2024
Q3 		$688K Buy
14,000
+400
+3% +$18.8K 0.04% 505
2024
Q2 		$613K Buy
13,600
+10,100
+289% +$343K 0.04% 457
2024
Q1 		$218K Buy
+3,500
New +$227K 0.01% 1068
2022
Q3 		– Sell
-1,037
Closed -$53K – 1743
2022
Q2 		$53K Sell
1,037
-2
-0.2% -$88 ﹤0.01% 1474
2022
Q1 		$43K Sell
1,039
-54
-5% -$2.83K ﹤0.01% 1499
2021
Q4 		$95K Buy
+1,093
New +$107K ﹤0.01% 1737

Other funds holding IRON

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Prelude Capital Management's IRON Position: Q1 2026 in Review

Prelude Capital Management sold out of Disc Medicine (IRON) in Q1 2026, closing a stake of 13,985 shares — an estimated $1.11M sold.

Prelude Capital Management first reported a position in IRON in Q4 2021 and held it in 11 quarters. The position peaked at $1.2M in Q3 2025. 203 funds tracked by Wall St. Rank hold IRON as of Q1 2026.

  • Prelude Capital Management reported no remaining Disc Medicine position as of Q1 2026 after selling out during the quarter.
  • Prelude Capital Management sold 13,985 Disc Medicine shares in Q1 2026, an estimated $1.11M.
  • Prelude Capital Management first reported a position in Disc Medicine in Q4 2021 and held it in 11 quarters.
  • Prelude Capital Management's Disc Medicine position peaked at $1.2M in Q3 2025.
  • 203 funds tracked by Wall St. Rank held Disc Medicine as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.